Skip Navigation

Nephrology Dialysis Transplantation 2006 21(Supplement 5):v4-v8; doi:10.1093/ndt/gfl474
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kuhlmann, M.
Right arrow Articles by Covic, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuhlmann, M.
Right arrow Articles by Covic, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

The protein science of biosimilars

Martin Kuhlmann1, and Adrian Covic2

1Department of Internal Medicine – Nephrology, Klinikum im Friedrichshain, Berlin, Germany and 2Dialysis and Transplantation Center, Parhon University Hospital, Romania

Correspondence and offprint requests to: Martin Kuhlmann, Klinikdirektor Innere Medizin – Nephrologie, Vivantes Klinikum im Friedrichshain, Landberger Allee 49, 10249 Berlin, Germany. Email: Martin.Kuhlmann{at}vivantes.de

A sea change is occurring in the off-patent drug manufacturing industry with a first wave of biotechnologically derived products reaching the end of their patent lives. However, recombinant proteins are in a different league from their chemical predecessors in terms of molecular complexity. Small differences in manufacturing processes can affect the efficacy and safety of the recombinant proteins in a manner which is not always measurable using analytical or in vitro techniques. Thus, comparable clinical profiles do not automatically follow from physicochemical likeness and can only be demonstrated through clinical studies. It is essential for patient safety that both innovator and biosimilar manufacturers ensure consistency in their production, by performing rigorous purity and activity profiling between batches, and implement tailored pharmacovigilance plans.

Keywords: assays; biopharmaceuticals; biosimilars; glycosylation; manufacturing; pharmacovigilance; physicochemistry


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
S. Gottlieb
Biosimilars: Policy, clinical, and regulatory considerations
Am. J. Health Syst. Pharm., July 15, 2008; 65(14_Supplement_6): S2 - S8.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.